Browsing by Author "Tabak, Fehmi"
Now showing items 1-3 of 3
-
Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta
Kabaçam, Gökhan; Wedemeyer, Heiner; Savaş, Berna; Dalekos, George; Tabak, Fehmi; İdilman, Ramazan; Erhardt, Andreas; Yalçın, Kendal; Bozdayı, Mithat A.; Bozkaya, Hakan; Manns, Michael; Dienes, Hans; Yurdaydın, Cihan; Keskin, Onur (WILEY-BLACKWELL, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2014)Background & Aims: Immunohistochemical assessment of liver tissue in chronic delta hepatitis (CDH) is underinvestigated. Aim of the study was (i) to assess variables associated with hepatitis D antigen (HDAg), hepatitis B ... -
Safety and Effectiveness of Tenofovir Alafenamide in the Turkish Population: A Systematic Review
Tabak, Fehmi; Yapali, Suna; Celen, Mustafa K.; Guner, Rahmet (Galenos Publ House, 2023)Hepatitis B virus infection is an important public health problem in the world and in Turkey. Nucleoside analogues and pegylated interferon-alpha are used as therapeutic agents in the management of chronic hepatitis B (CHB) ... -
Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta
Wranke, Anika; Hardtke, Svenja; Heidrich, Benjamin; Dalekos, George; Yalçın, Kendal; Tabak, Fehmi; Gürel, Selim; Çakaloglu, Yılmaz; Akarca, Ulus S.; Lammert, Frank; Haeussinger, Dieter; Mueller, Tobias; Woebse, Michael; Manns, Michael P.; İdilman, Ramazan; Cornberg, Markus; Wedemeyer, Heiner; Yurdaydın, Cihan (Wiley, 2020)Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. PEG-interferon alpha-2a (PEG-IFN alpha-2a) is the only effective treatment but its long-term clinical impact is unclear. The aim of this ...
